UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 000-51122 EyePoint Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorpo ...

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q2 2021 Earnings Conference Call August 4, 2021 8:30 AM ET Company Participants George Elston - Chief Financial Officer & Head, Corporate Development Nancy Lurker - President & Chief Executive Officer Jay Duker - Chief Strategic Scientific Officer Scott Jones - Chief Commercial Officer Conference Call Participants Jennifer Kim - Cantor Fitzgerald Georgi Yordanov - Cowen and Company Yatin Suneja - Guggenheim Partners Yi Chen - H.C. Wainwright Yale Jen - Laidlaw An ...

Financial Data and Key Metrics Changes - For Q1 2021, total net revenue was $7.3 million, a decrease from $7.5 million in Q1 2020. Net product revenue was $6.8 million, up 45% from $4.7 million in Q1 2020 [20][21] - The net loss for Q1 2021 was $12.3 million, or $0.50 per share, compared to a net loss of $13.2 million, or $1.14 per share, in the prior year [21] - Cash and cash equivalents at March 31, 2021, totaled $138.6 million, significantly up from $44.9 million at December 31, 2020 [21] Business Line Data and Key Metrics Changes - Net product revenue for YUTIQ was $3.8 million and for DEXYCU was $3 million in Q1 2021, with customer demand for DEXYCU at approximately 7,000 units and for YUTIQ at 400 units [16] - The introduction of a new siliconized needle for YUTIQ is expected to enhance patient and physician experience [8][17] Market Data and Key Metrics Changes - The company reported a strong first quarter despite the ongoing challenges of the COVID-19 pandemic, with a 45% increase in net product revenues compared to the previous year [8][15] - The Asia partner, Ocumension Therapeutics, received approval for review of a new drug application for YUTIQ in China, indicating potential for future revenue streams [9] Company Strategy and Development Direction - The company aims to expand its product pipeline and drive growth for its commercial products, targeting profitability for DEXYCU and YUTIQ by year-end [9][18] - Plans to initiate studies for EYP-1901 in diabetic retinopathy and retinal vein occlusion are underway, with hopes to start these studies in late 2021 or early 2022 [7][14] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth of the Wet AMD market due to the aging population and the need for innovative treatment options [24] - The company remains focused on maintaining a strong balance sheet and disciplined spending to support its growth initiatives [9][21] Other Important Information - The company successfully completed a $115.1 million follow-on offering to strengthen its balance sheet [7] - The revenue covenant with CRG was reduced to $25 million at no cost, reflecting improved financial conditions [8][20] Q&A Session Summary Question: How will the Wet AMD space evolve over the next 5 to 10 years? - Management believes the demand will continue to grow due to the aging population and the prevalence of the disease, with a place for innovative drugs like EYP-1901 [24][25] Question: What are the opportunities in other retinal indications? - The company is evaluating studies in diabetic retinopathy and retinal vein occlusion, which are large patient populations [28] Question: Can you provide spending guidance for the year? - Q1 spending is a good run rate, with expectations for continued investment in clinical trials [30][31] Question: What is the status of the SEC investigation? - The SEC concluded its investigation with no intent to recommend enforcement action, which the company views positively [36][37] Question: What trends are seen in retinal specialists and ASCs? - Most cataract surgery centers are returning to normal, though some academic centers still face restrictions [38] Question: What is the expected efficacy of EYP-1901 compared to existing treatments? - Management believes that extended delivery could lead to better patient outcomes, although long-term studies are needed to confirm this [56]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 000-51122 EyePoint Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorp ...

Delivering Innovation to the Eye Investor Presentation March 2021 1 | EYEPOINT PHARMACEUTICALS Forward Looking Statements Various statements made in this presentation are forward-looking, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. All statements that address activities, events or developments that we intend, expect, plan or believe may occur in the future, including but not limited to statements about our expectations regarding the potential benefits of our pa ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-51122 EyePoint Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 26-2774444 (State or other jurisdiction of in ...

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q4 2020 Earnings Conference Call March 4, 2021 8:30 AM ET Company Participants George Elston – Chief Financial Officer Nancy Lurker – President and Chief Executive Officer Jay Duker – Chief Strategic Scientific Officer Scott Jones – Chief Commercial Officer Dario Paggiarino – Senior Vice President and Chief Medical Officer Conference Call Participants Jennifer Kim – Cantor Fitzgerald Dana Flanders – Guggenheim Yale Jen – Laidlaw and Company Andrew D'Silva – B. Ri ...

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q3 2020 Results Earnings Conference Call November 5, 2020 8:30 AM ET Company Participants George Elston - Chief Financial Officer Nancy Lurker - President and CEO Jay Duker - Chief Strategic Scientific Officer Scott Jones - Chief Commercial Officer Dario Paggiarino - Senior Vice President and CMO Conference Call Participants Andrew D'Silva - B. Riley Operator Good morning. My name is Bridget, and I’ll be your conference operator today. At this time, I would like ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 000-51122 EyePoint Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of in ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 000-51122 EyePoint Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorpo ...